Focal Laser Treatment Shows Promise for Prostate Cancer with Minimal Impact on Function

What is it about?

This article presents a systematic review and meta-analysis of focal laser ablation (FLA) in the management of localized prostate cancer, following PRISMA guidelines. The study included 12 studies with a total of 421 patients and focused on oncological control, assessed by recurrence rate and PSA level reduction, as well as secondary outcomes like adverse events and functional outcomes related to sexual and urinary function. The findings indicate that FLA results in a recurrence rate of 15% for clinically significant cancer and a mean PSA reduction of 2.3 ng/mL at 12 months post-treatment. While FLA showed a statistically significant decrease in sexual function, it was not clinically significant, and there was no significant change in urinary function. The article highlights the heterogeneity in patient selection, follow-up protocols, and definitions of recurrence, which limits the generalizability of findings across studies. It concludes with a call for further high-quality, long-term studies to better define the role of FLA in prostate cancer care.

Featured Image

Why is it important?

This review examines the effectiveness of focal laser ablation (FLA) in managing localized prostate cancer, aiming to provide insights into its oncological control and functional outcomes. The relevance of this review lies in its evaluation of FLA as a treatment option that potentially balances effective cancer control with the preservation of urinary and sexual function, compared to more invasive treatment methods such as radical prostatectomy and radiotherapy, which are associated with significant long-term side effects. Key Takeaways: 1. The review compiles evidence suggesting that FLA offers oncological control comparable to other focal therapies, with a recurrence rate of clinically significant cancer on biopsy at 15% and a mean PSA level reduction of 2.3 ng/mL at 12 months post-treatment. 2. Functional outcomes post-FLA are favorable, with a statistically significant but clinically minor decrease in sexual function and no significant change in urinary function, indicating FLA’s potential advantage in preserving quality of life. 3. Despite the promising findings, the review highlights the challenges in comparing FLA with other treatments due to heterogeneity in study designs and emphasizes the need for high-quality, long-term studies to better define FLA’s role in prostate cancer management.